Press release
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Total product and royalty revenues of $778 million in Q3 2021 (+25% vs. Q3 2020); Jakafi® (ruxolitinib) revenues of $547 million in Q3 2021 (+12% vs. Q3
About this update from Incyte Corporation
[{"type":"text","content":"\n\nTotal product and royalty revenues of $778 million in Q3 2021 (+25% vs. Q3 2020); Jakafi® (ruxolitinib) revenues of $547 million in Q3 2021 (+12% vs. Q3 2020)\n\n\nThree regulatory approvals including OpzeluraTM (ruxolitinib) cream in the U.S. for the treatment of atopic dermatitis, Jakafi in the U.S. for the treatment of chronic graft-versus-host disease (GVHD) and Minjuvi® (tafasitamab) in Europe for the treatment of relapsed or refractory DLBCL\n\n\nPivotal TRuE-V data presentation at EADV highlighted significant improvements in facial and total body repigmentation in vitiligo patients treated with ruxolitinib cream; Company pursuing regulatory approvals in the U.S. and Europe\n\n\nConference Call and Webcast Scheduled Today at 8:00 a.m. EDT\n\n WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today reports 2021 third quarter financial results and provides a status update on the Company’s development portfolio.\n\n“Incyte has transformed as a Company over the last two years, as we deliver on our goal of diversifying and growing our revenue,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “Multiple product approvals and global launches have significantly expanded our portfolio; our robust development pipeline continues to mature and progress; and we expect several additional regulatory submissions to occur over the coming months. Our strong third quarter performance is the result of an increasingly diversified portfolio, driven by double-digit growth in patient demand for Jakafi® (ruxolitinib), continued uptake of both Pemazyre® (pemigatinib) and Monjuvi®/Minjuvi® (tafasitamab) as well as a significant and rapidly-growing royalty revenue stream.”\n\nPortfolio Update\n\nMPNs and GVHD – key highlights\n\nJakafi approval in chronic graft-versus-host disease (GVHD): In September, the U.S. Food and Drug Administration (FDA) granted approval of Jakafi for the treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. There are approximately 14,000 people in the U.S. living with chronic GVHD, with more than half requiring therapy beyond systemic corticosteroids.\n\nCollaboration with Syndax Pharmaceuticals: In September, Incyte and Syndax Pharmaceuticals announced an exclusive worldwide collaboration and license agreement to develop and comme...